InscoBi, Consecutive Participant in Korea's Largest 'Bio Korea 2022'

[Asia Economy Reporter Hyungsoo Park] InscoBi announced on the 11th that it will showcase its technological capabilities along with its affiliates at 'Bio Korea 2022,' held at COEX, Seoul, until the 13th.

Celebrating its 17th anniversary this year, Bio Korea 2022 is an event hosted by the Korea Health Industry Development Institute and Chungcheongbuk-do Province. The theme is 'Post-COVID and Future Innovative Technologies.'

Through the event, InscoBi will share research achievements and development strategies in the bio business sector. Along with InscoBi, bio affiliates such as Cellumed, Apimez, and BigBio are also participating, expecting significant synergy effects.

InscoBi sells the dermocosmetic brand 'Themicoce,' based on Cellumed's patented material. 'Themicoce' is a cosmeceutical brand containing the growth factor FGF7, which matches 100% with the human skin DNA sequence.

Cellumed, listed on KOSDAQ, possesses outstanding technology in artificial joints and growth factors. Since last year, it has been accelerating the development of 'mRNA vaccine and therapeutic enzyme production.' Through active collaboration from the development stage with German companies Artes and Richter Hem Biologics (RHB), development is progressing smoothly. By the end of this year, it plans to complete production process development for GMP (manufacturing facilities) technology transfer and the development of cGMP (current Good Manufacturing Practice) level analysis and quality control technologies.

Apimez is strengthening its pipeline based on bee venom and expanding its formulation business. Earlier this year, BigBio received New Excellent Technology (NET) certification from the Ministry of Health and Welfare for the 'method of diagnosing cancer using MARS1 antibody' and is currently developing cancer diagnostic reagents and kits utilizing MARS1.

This content was produced with the assistance of AI translation services.